Treatment of Klebsiella Infections
For carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, use combination therapy with at least two drugs active in vitro, prioritizing newer beta-lactam/beta-lactamase inhibitors (meropenem-vaborbactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam) as first-line agents when available 1, 2.
Treatment Algorithm Based on Resistance Pattern
Non-Resistant (Antibiotic-Susceptible) Klebsiella
- Use cefazolin or ceftriaxone as definitive therapy for bacteremia caused by susceptible strains 3
- Cefazolin is equally effective as ceftriaxone (28-day mortality 10.5% vs 7.1%, p=0.403) and serves as a ceftriaxone-sparing alternative 3
- This approach reduces selection pressure for ESBL development
Carbapenem-Resistant Klebsiella (CRKP)
Severe Infections (High INCREMENT Score 8-15, Septic Shock, Bacteremia):
- Mandatory combination therapy with ≥2 in vitro active drugs 1, 4
- The evidence strongly favors combination over monotherapy in severe disease, with adjusted HR 0.56 (95% CI 0.34-0.91) for 30-day mortality 1
- Combination therapy reduces clinical failure, microbiological failure, and 30-day mortality (all p≤0.003) 4
Preferred First-Line Combinations:
- New beta-lactam/beta-lactamase inhibitors (meropenem-vaborbactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam) plus a second active agent 1, 2
- Polymyxin B-based combinations if newer agents unavailable:
- Fosfomycin-containing combinations (with tigecycline, polymyxin, or carbapenems) showed RR 0.55 for mortality 6
Carbapenem Use in CRKP:
- Avoid carbapenem-based combinations unless meropenem MIC ≤8 mg/L 1
- When MIC ≤8 mg/L, use high-dose extended-infusion meropenem as part of combination therapy 1
- Carbapenem-containing and carbapenem-sparing regimens show similar outcomes (p=0.81) 4
Non-Severe or Low-Risk CRKP Infections:
- Monotherapy with a single in vitro active agent may be considered on an individual basis according to infection source 1
- This applies only when INCREMENT score <8 and patient is not in septic shock
Critical Implementation Considerations
Therapeutic Drug Monitoring (TDM)
Perform TDM for the following drugs when treating CRKP 6:
- Polymyxins (narrow therapeutic index, life-threatening toxicity risk)
- Aminoglycosides (reduces nephrotoxicity from 13.4% to 2.8%, improves mortality) 6
- Carbapenems (especially high-dose continuous infusion meropenem)
TDM is particularly crucial in:
- Critical illness/sepsis
- Renal dysfunction or augmented renal clearance
- CNS infections or bloodstream infections (difficult-to-reach sites)
Common Pitfalls to Avoid
Do not use monotherapy for severe CRKP infections - The evidence consistently shows worse outcomes with single-agent therapy in high-risk patients 1, 4
Do not assume carbapenemase production affects mortality - Presence or absence of carbapenemase production does not independently affect mortality rate (p=0.26) 4, so focus on in vitro susceptibility rather than resistance mechanism
Do not use fosfomycin monotherapy - While fosfomycin shows synergistic activity, it should only be used in combination due to variable susceptibility (39-99%) and risk of resistance development 6
Verify colistin/polymyxin susceptibility carefully - Elevated non-susceptibility has been reported, but requires proper broth microdilution testing for accurate results 7
Nuances in Evidence Quality
The guideline evidence 1 acknowledges very low certainty due to highly variable definitions of "combination therapy" across studies (2-5 antibiotics with variable activity, dosages, and durations). However, the consistent signal favoring combination therapy in severe disease across multiple adjusted analyses provides sufficient evidence for the recommendation, particularly when combination is defined as ≥2 in vitro active agents 1, 4.
The 2022 ESCMID guidelines 1 represent the highest quality, most recent comprehensive guidance and should frame all treatment decisions, with the 2023 Asian guidelines 6 providing supportive evidence for specific drug combinations and TDM practices.